Universal Cancer Vaccine Enters Phase III Trials

The Universal Cancer Vaccine from Moderna and BioNTech entered Phase III trials in 2025, showing a 52% reduction in recurrence rates for melanoma—a 50% higher efficacy than the average vaccine candidate. Outperforming #2’s typical 30% reduction in earlier cancer vaccines, this mRNA-based approach targets tumor neoantigens using personalized platforms. Phase II data from 400 patients demonstrates concrete 60% lower recurrence in pancreatic cancer, a 20% improvement over standard therapies, promising transformative oncology treatments within a decade.